Defoslimod
Alternative Names: OM-174; OM-174-DPLatest Information Update: 08 Oct 2020
At a glance
- Originator OM Pharma
- Class Adjuvants; Antineoplastics; Glycoconjugates
- Mechanism of Action Immunostimulants; Macrophage stimulants; Toll-like receptor 4 modulators; Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Sep 2020 OM Pharma has been acquired by Optimus Holding
- 01 May 2014 Discontinued - Phase-I for Cancer in Switzerland (Parenteral)
- 24 Feb 2011 Phase-Ib development is ongoing in Switzerland